Rapport Therapeutics (RAPP) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$1.19
- Estimate
- -$0.99
- Surprise
- -20.4%
- Score today
- 4.8/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Rapport Therapeutics (RAPP) reported a wider loss than forecast — adjusted EPS of -$1.19 against the -$0.99 estimate (a 20.4% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates RAPP Sell at 4.8/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -20.4% surprise compares with a +4.1% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: RAP-219
- Quality below floor (2.0 < 4.0)
- Value-trap signals (2/5): Revenue declining (-22.6% YoY), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $28.99
- Price target
- $54.85
- Stop
- $27.82
- Upside to target
- +89.2%
- Reward-to-risk
- 7.3:1
Risk check: RSI 18 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
RAPP at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.39B
- P/E (fwd)
- -5.7
- 52-week range
- $23.75–$52.93
- Off 52-week high
- 45.2%
- RSI (14)
- 18
- Volume vs avg
- 0.64×
- Score today
- 4.8/10